Shareholders Reject Officer Exculpation Amendment at Annual Meeting
CAPR has more than doubled off its 52-week low of $4.3.
Summary
Capricor Therapeutics held its Annual Meeting, where shareholders elected directors and approved executive compensation, but notably rejected a proposal for officer exculpation.
Key Events · Corporate Governance and Compliance · CAPR
-
Annual Meeting Held
The Annual Meeting of stockholders was held on June 4, 2026, with 43,823,881 shares represented, constituting a quorum.
-
Board of Directors Elected
All eight nominated directors, including Frank Litvack, M.D., and Linda Marbán, Ph.D., were elected to serve until the 2027 annual meeting.
-
Officer Exculpation Amendment Rejected
Shareholders did not approve an amendment to the Certificate of Incorporation regarding officer exculpation, with 6,433,198 votes against compared to 23,472,207 for, and 887,987 abstentions.
-
Executive Compensation Approved
The non-binding advisory vote to approve named executive officer compensation passed, and shareholders preferred an annual frequency for future votes on executive compensation.
Analysis · CAPR · Life Sciences
Shareholders rejected a proposal to amend the Certificate of Incorporation to include officer exculpation. This outcome indicates a desire for increased accountability from the company's officers, potentially exposing them to greater personal liability for certain actions. This decision reflects shareholder sentiment regarding corporate governance, especially in light of the company's recent lawsuit against its U.S. distributor.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.1% of the 1692 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CAPR was trading at $26.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $4.30 to $40.37. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.